UPDATE: CRISPR Therapeutics (CRSP) PT Raised to $59 at Barclays, Street High – StreetInsider.com
The Ledger Gazette |
UPDATE: CRISPR Therapeutics (CRSP) PT Raised to $59 at Barclays, Street High
StreetInsider.com Barclays raised its price target on CRISPR Therapeutics (NASDAQ: CRSP) to $59.00 (from $29.00) while maintaining a Overweight rating. Analyst Gena Wang comments "Given continual ongoing development as evidenced by recent data from multiple companies … ARK Investment Management LLC Has $737000 Stake in Crispr Therapeutics AG (NASDAQ:CRSP) Somewhat Favorable News Coverage Somewhat Unlikely to Affect Crispr Therapeutics (CRSP) Stock Price Analyst Opinion Summary: CRISPR Therapeutics AG (CRSP), Depomed, Inc. (DEPO) |
